Skip to content
HowShorted

Coherus Oncology, Inc. short interest in 2020

In 2020, Coherus Oncology, Inc.'s disclosed short interest ran from 15.36% of shares outstanding on 15 Jan 2020 to 21.50% on 31 Dec 2020, a change of +6.14 percentage points. The year's high was 27.32% on 15 Jul 2020 and its low 15.10% on 15 Apr 2020, averaging 21.29% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 27.27 days on 31 Aug 2020. Full history: Coherus Oncology, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Coherus Oncology, Inc. in 2020

2020 in figures

Start of year
15.36% (15 Jan 2020)
End of year
21.50% (31 Dec 2020)
Change
+6.14 pp
High
27.32% (15 Jul 2020)
Low
15.10% (15 Apr 2020)
Average
21.29%
Highest days to cover
27.27 (31 Aug 2020)
SEC filings marked
9

Every report in 2020

Coherus Oncology, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202015.36%10.25
31 Jan 202015.61%14.46
14 Feb 202016.47%9.66
28 Feb 202016.71%9.9210-K filed, results (8-K)
13 Mar 202016.45%9.07
31 Mar 202015.56%7.87
15 Apr 202015.10%8.26results (8-K)
30 Apr 202019.06%7.95
15 May 202019.77%13.6110-Q filed, results (8-K)
29 May 202021.75%7.52
15 Jun 202025.79%14.73
30 Jun 202026.67%14.71
15 Jul 202027.32%20.03
31 Jul 202026.07%24.59
14 Aug 202025.20%15.4010-Q filed, results (8-K)
31 Aug 202025.99%27.27
15 Sep 202026.40%23.11
30 Sep 202024.85%20.60
15 Oct 202023.46%18.98
30 Oct 202022.74%19.64
13 Nov 202021.88%17.8210-Q filed, results (8-K)
30 Nov 202021.08%24.40
15 Dec 202020.27%23.10
31 Dec 202021.50%18.16

See also: Coherus Oncology, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.